Search Results

Apollomics Inc. announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.

Predicine, Inc., a leading molecular insights company, announced a collaboration with Apollomics, Inc.

Apollomics Inc. announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.

Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced that it entered into subscription agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses.

Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET.

Apollomics Inc. (“Apollomics” or the “Company”) today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET.

Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets.